Assessment of rhEPO in pharmaceutical formulations by a reversed-phase liquid chromatography method and bioassay

Journal of Liquid Chromatography and Related Technologies

Volumn 30, Issue 9-10, 2007, Pages 1277-1288

  Barth, Thiago ^a   Sangoi, Maximiliano Da Silva ^a   Silva, Lucélia Magalhães Da ^a   Ferretto, Ricardo Machado ^a   Dalmora, Sérgio Luiz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Normocythaemic mice bioassay; Recombinant human erythropoietin (rhEPO); Reversed phase liquid chromatography; Validation

Indexed keywords

ACETIC ACID; BIOASSAY; LIQUID CHROMATOGRAPHY; PHOTODIODES; PORE SIZE; RATS;

NORMOCYTHAEMIC MICE BIOASSAYS; PHOTODIODE ARRAY (PDA); RECOMBINANT HUMAN ERYTHROPOIETIN (RHEPO); REVERSED PHASE LIQUID CHROMATOGRAPHY;

DRUG PRODUCTS;

ACETONITRILE; RECOMBINANT ERYTHROPOIETIN; TRIFLUOROACETIC ACID;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RETENTION; ELUTION; FEMALE; FLOW RATE; MOUSE; NONHUMAN; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY;

MUS;

EID: 34147188070     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070701274668     Document Type: Article

References (24)

1. Krantz, S.B. Erythropoietin. Blood 1991, 77, 419-434.
2. Elliot, S.; Egrie, J.; Browne, J.; Lorenzini, T.; Busse, L.; Rogers, N.; Ponting, I. Control of rHuEPO biological activity: The role of carbohydrate. Exp. Hematol. 2004, 32, 1146-1155.
3. Egrie, J.C.; Dwyer, E.; Browne, J.K.; Hitz, A.; Lykos, M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 2003, 31, 290-299.
4. Ramakrishnan, R.; Cheung, W.K.; Wacholtz, M.C.; Minton, N.; Jusko, W.J. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol. 2004, 44, 991-1002.
5. Gascón, P. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur. J. Cancer 2005, 41, 2601-2612.
6. Storring, P.L.; Gaines Das, R.E. The international standard for recombinant DNAderived erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J. Endocrinol. 1992, 134, 459-484.
7. Bristow, A. III Collaborative study for the establishment of a biological reference preparation for erythropoietin. Pharmeuropa 1997, 2, 31-47.
8. Liefooghe, E.C.; Tiplady, R.; Gerson, P.; Lloyd, P.; Heath, A.; Bristow, A.F. A sialylation-sensitive cell-based in vitro bioassay for erythropoietin; incorporation of the galactose-binding Erythrina crista-galli lectin. Biologicals 2005, 33, 161-167.
9. Kawamura, A.; Imai, N.; Kawaguchi, T.; Hayakawa, T. Simple in vivo bioassay for erythropoietin. Br. J. Haematol. 1991, 77, 424-430.
10. Ramos, A.S.; Schmidt, C.A.; Andrade, S.S.; Fronza, M.; Rafferty, B.; Dalmora, S.L. Biological evaluation of recombinant human erythropoietin in pharmaceutical products. Braz. J. Med. Biol. Res. 2003, 36, 1561-1569.
11. European Pharmacopoeia, 5th Ed.; Council of Europe: Strasbourg, France, 2005.
12. Bristow, A.F.; Jeffcoate, S.L. Analysis of therapeutic growth hormone preparations: Report of an inter-laboratory collaborative study on growth hormone assay methodologies. Biologicals 1992, 20, 221-231.
13. Mire-Sluis, A.R.; Gerrard, T.; Das, R.G.; Padilha, A.; Thorpe, R. Biological assays: Their role in the development and quality control of recombinant biological medicinal products. Biologicals 1996, 24, 351-362.
14. Dalmora, S.L.; Masiero, S.M.K.; Oliveira, P.R.; Sangoi, M.S.; Brum Junior, L. Validation of an RP-LC Method and Assessment of rhG-CSF in pharmaceutical formulations by liquid chromatography and biological assay. J. Liq. Chromatogr. & Rel. Technol. 2006, 29, 1753-1767.
15. Bietlot, H.P.; Girard, M. Analysis of recombinant human erythropoietin in drug formulations by high-performance capillary electrophoresis. J. Chromatogr. A 1997, 759, 177-184.
16. Lara-Quintanar, P.; Lacunza, I.; Sanz, J.; Diez-Masa, J.C.; de Frutos, M. Immunochromatographic removal of albumin in erythropoietin biopharmaceutical formulations for its analysis by capillary electrophoresis. J. Chromatogr. A 2006, in press.
17. Wang, W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Intl. J. Pharm. 1999, 185, 129-188.
18. Rao, R.N.; Nagaraju, V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. J. Pharm. Biomed. Anal. 2003, 33, 335-377.
19. Ribela, M.T.C.P.; Gout, P.W.; Oliveira, J.E.; Bartolini, P. HPLC Analysis of Human Pituitary Hormones for Pharmaceutical Applications. Curr. Pharm. Anal. 2006, 2, 103-126.
20. Gunturi, S.R.; Ghobrial, I.; Sharma, B. Development of a sensitive size exclusion HPLC method with fluorescence detection for the quantitation of recombinant human erythropoietin (r-HuEPO) aggregates. J. Pharm. Biomed. Anal. 2007, 43, 213-221.
21. Luykx, D.M.A.M.; Dingemanse, P.J.; Goerdayal, S.S.; Jongen, P.M.J.M. Highperformance anion-exchange chromatography combined with intrinsic fluorescence detection to determine erythropoietin in pharmaceutical products. J. Chromatogr. A 2005, 1078, 113-119.
22. Ahrer, K.; Jungbauer, A. Chromatographic and electrophoretic characterization of protein variants. J. Chromatogr. B 2006, 841, 110-122.
23. Finney, D.J. Statistical Methods in Biological Assay; Charles Griffin: London, 1978.
24. International Conference on Harmonisation (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use, Validation of Analytical Procedures: Text and Methodology Q2(R1), November 2005; 1-13.